Related references
Note: Only part of the references are listed.Risk for Recurrent Venous Thromboembolism and Bleeding With Apixaban Compared With Rivaroxaban: An Analysis of Real-World Data
Ghadeer K. Dawwas et al.
ANNALS OF INTERNAL MEDICINE (2022)
2019 ESC Guidelines for the dignosis and management of acute pulmonary embolism development Toed in colaboration with the European Respiratory Society (ERS)
Stavros Konstantinides et al.
EUROPEAN HEART JOURNAL (2020)
Comparative effectiveness and safety of apixaban versus warfarin in patients with venous thromboembolism
Ghadeer K. Dawwas et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2020)
Methodological considerations when analysing and interpreting real-world data
Til Sturmer et al.
RHEUMATOLOGY (2020)
Diagnosis and Treatment of Lower Extremity Venous Thromboembolism: A Review
Romain Chopard et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis
Faizan Khan et al.
BMJ-BRITISH MEDICAL JOURNAL (2019)
It's time for head-to-head trials with direct oral anticoagulants
Tobias Tritschler et al.
THROMBOSIS RESEARCH (2019)
Effectiveness and safety of rivaroxaban versus warfarin in patients with unprovoked venous thromboembolism: A propensity-score weighted administrative claims cohort study
Craig I. Coleman et al.
THROMBOSIS RESEARCH (2018)
Matching Weights to Simultaneously Compare Three Treatment Groups Comparison to Three-way Matching
Kazuki Yoshida et al.
EPIDEMIOLOGY (2017)
Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism
J. I. Weitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Protocol for a randomised controlled trial of the effect of dapagliflozin, metformin and exercise on glycaemic variability, body composition and cardiovascular risk in prediabetes (the PRE-D Trial)
Kristine Færch et al.
BMJ Open (2017)
Comparative safety of direct oral anticoagulants and warfarin in venous thromboembolism: multicentre, population based, observational study
Min Jun et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Comparative safety of direct oral anticoagulants and warfarin in venous thromboembolism: multicentre, population based, observational study
Min Jun et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study
Torben B. Larsen et al.
LANCET HAEMATOLOGY (2017)
When and How Can Real World Data Analyses Substitute for Randomized Controlled Trials?
Jessica M. Franklin et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
A single dose of dapagliflozin, an SGLT-2 inhibitor, induces higher glycosuria in GCK- and HNF1A-MODY than in type 2 diabetes mellitus
J. Hohendorff et al.
ENDOCRINE (2017)
Antithrombotic Therapy for VTE Disease CHEST Guideline and Expert Panel Report
Clive Kearon et al.
CHEST (2016)
Comparison of the Non-VKA Oral Anticoagulants Apixaban, Dabigatran, and Rivaroxaban in the Extended Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis
A. T. Cohen et al.
PLOS ONE (2016)
Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis
Sam Schulman et al.
CIRCULATION (2014)
Metrics for covariate balance in cohort studies of causal effects
Jessica M. Franklin et al.
STATISTICS IN MEDICINE (2014)
Incidence of and Mortality from Venous Thromboembolism in a Real-world Population: The Q-VTE Study Cohort
Vicky Tagalakis et al.
AMERICAN JOURNAL OF MEDICINE (2013)
A Weighting Analogue to Pair Matching in Propensity Score Analysis
Liang Li et al.
INTERNATIONAL JOURNAL OF BIOSTATISTICS (2013)
Apixaban for Extended Treatment of Venous Thromboembolism
Giancarlo Agnelli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
Harry R. Bueller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism
Sam Schulman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Giancarlo Agnelli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies
Martin H. Prins et al.
THROMBOSIS JOURNAL (2013)
Role of disease risk scores in comparative effectiveness research with emerging therapies
Robert J. Glynn et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2012)
A systematic review of validated methods for identifying venous thromboembolism using administrative and claims data
Leonardo Tamariz et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2012)
A combined comorbidity score predicted mortality in elderly patients better than existing scores
Joshua J. Gagne et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2011)
An automated database case definition for serious bleeding related to oral anticoagulant use
Andrew Cunningham et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2011)
A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation The Euro Head Survey
Ron Pisters et al.
CHEST (2010)
Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples
Peter C. Austin
STATISTICS IN MEDICINE (2009)